ASND · Ascendis Pharma AS

-

Please sign in to comment on ASND

1 Comment

Admin

4 years ago

Ascendis Pharma A/S is currently in a long term downtrend where the price is trading 16.7% below its 200 day moving average.

From a valuation standpoint, the stock is 39.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 809.8.

Ascendis Pharma A/S's total revenue sank by 78.7% to $535K since the same quarter in the previous year.

Its net income has dropped by 72.9% to $-139M since the same quarter in the previous year.

Finally, its free cash flow fell by 89.7% to $-96M since the same quarter in the previous year.

Based on the above factors, Ascendis Pharma A/S gets an overall score of 1/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US04351P1012

PE Ratio	None
Market Cap	10B
Target Price	214.2287
Beta	0.54
Dividend Yield	None

ABOUT

Ascendis Pharma AS

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.

ASND · Ascendis Pharma AS

-

Ascendis Pharma AS

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Ascendis Pharma AS using a moving average strategy